Journal of the American College of Cardiology
-
J. Am. Coll. Cardiol. · Jun 2019
Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of blood cholesterol found little evidence to support the use of nonstatin lipid-modifying medications to reduce atherosclerotic cardiovascular disease (ASCVD) events. Since publication of these guidelines, multiple randomized controlled trials evaluating nonstatin lipid-modifying medications have been published. ⋯ In a systematic review of the evidence for adding nonstatin lipid-modifying therapies to statins to reduce ASCVD risk, we found evidence of benefit for ezetimibe and PCSK9 inhibitors but not for niacin or cholesterol-ester transfer protein inhibitors.
-
J. Am. Coll. Cardiol. · Jun 2019
Meta AnalysisAspirin for Primary Prevention of Cardiovascular Events.
The efficacy and safety of aspirin for primary prevention of cardiovascular disease (CVD) remain debatable. ⋯ Aspirin for primary prevention reduces nonfatal ischemic events but significantly increases nonfatal bleeding events.
-
J. Am. Coll. Cardiol. · Jun 2019
Randomized Controlled Trial Multicenter Study Comparative StudyTicagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial.
The efficacy of ticagrelor in the long-term post-ST-segment elevation myocardial infarction (STEMI) treated with fibrinolytic therapy remains uncertain. ⋯ Among patients age <75 years with STEMI, administration of ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of cardiovascular events when compared with clopidogrel. (Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis [TREAT]; NCT02298088).